跳至主要内容
临床试验/NCT01823965
NCT01823965已完成2 期

Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment

Poitiers University Hospital1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2011年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
35
试验地点
1
主要终点
Number of intravitreal injections of ranibizumab

研究概览

简要总结

In the prospective monocentric open label trial patients with diabetic macular edema will be treated with intravitreal injections of ranibizumab given for 3 months then with laser grid at month 4. During follow-up a ranibizumab injection will be performed every 2 months in case of best-corrected visual acuity decreased more than 5 letters.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diabetes mellitus (1 or2)
  • decreased vision from Diabetic Macular Edema (study eye Best Corrected Visual Acuity<69 letters using E.T.D.R.S testing)
  • macular edema

排除标准

  • history of severe cardiac disease
  • stroke within 12 months
  • intraocular inflammation

研究组 & 干预措施

ranibizumab

Experimental

干预措施: ranibizumab (Drug)

结局指标

主要结局

Number of intravitreal injections of ranibizumab

时间窗: 1 years

次要结局

  • best-corrected visual acuity(1 years)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Intravitreal Injections of Ranibizumab With Deferred... | 临床试验